Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering

LAVAL, QC and VAUGHAN, ON, January 13, 2022 /CNW/ – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) today announced that, as part of its previously announced intention to spin off its eye health business, its wholly owned subsidiary , Bausch + Lomb Corporation (“Bausch + Lomb”), has publicly filed a registration statement on Form S-1 with the United States Securities and Exchange Commission (“SEC”) and a preliminary pricing proceeding prospectus post-receipt (“PREP”) with the securities regulatory authority in each of the provinces and territories of Canada (other than Quebec) (“Canadian regulators”) regarding a proposed initial public offering (“IPO”) of common stock of Bausch + Lomb concurrently in United States and Canada. All of the shares offered will be sold by a wholly-owned subsidiary of Bausch Health. The number of common shares to be offered and the price range for the IPO have not yet been determined.

Morgan Stanley and Goldman Sachs & Co. LLC are acting as co-lead bookkeepers for the IPO. JP Morgan, Citigroup, Barclays, BofA Securities, Guggenheim Securities, Jefferies, Evercore ISI, Wells Fargo Securities and Deutsche Bank Securities are acting as joint bookrunners for the IPO, and DNB Markets, HSBC and Truist Securities are acting as as co-managers for the IPO.

The listing on the stock exchange will be done only by means of a prospectus. Copies of the prospectus and the preliminary PREP base prospectus, when available, may be obtained from Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by phone at (866) 471-2526 or by email at [email protected]

The registration statement relating to the proposed offering has been filed with the SEC but has not yet become effective. The PREP Preliminary Base Prospectus contains important information relating to the common shares and remains subject to addition or amendment. The common shares may not be sold or offers to buy accepted until the registration statement becomes effective and a receipt for the final long form prospectus of the base PREP has been issued by the regulatory authorities. Canadian.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, and there will be no sale of these securities in any state, province, territory or jurisdiction in which any such offer, solicitation or sale would be unlawful. prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction. Any offer, solicitation or offer to buy or sell securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended and otherwise in accordance with applicable securities laws in any other jurisdiction. The IPO is subject to market conditions, and there can be no assurance that the IPO will occur or when, or as to the actual size or terms of the IPO.

About Bausch + Lomb
Bausch + Lomb, a leading global eye health company of Bausch Health Companies, Inc., is dedicated to protecting and enhancing the gift of sight for millions of people around the world, from moment of birth at every stage of life. Its comprehensive portfolio of over 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products, and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and sales footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, ON with headquarters in Bridgewater, New Jersey.

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) is a global company whose mission is to improve people’s lives through our healthcare products. Bausch Health develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. Bausch Health delivers on its commitments by building an innovative company dedicated to advancing global health.

Forward-looking statements
This press release may contain forward-looking statements regarding a possible IPO or transaction involving Bausch + Lomb, which can generally be identified by the use of the words “anticipates”, “hopes”, “expects”, ” intends’, ‘plans’, ‘should’, ‘could’, ‘should’, ‘may’, ‘believes’, ‘estimates’, ‘potential’, ‘target’ or ‘continues’ and variations or similar expressions , including statements about the timing of completion of the IPO, the price of common stock to be issued pursuant to the IPO, and the subsequent distribution of Bausch + Lomb stock to shareholders of Bausch Health ( including the intended means of effecting the distribution and whether Bausch Health shareholders may consider it). These statements are based on management’s current expectations and beliefs and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties identified in the IPO prospectus; risks relating to the transaction not being completed on time, if at all, including due to unfavorable market or other conditions or factors; risks relating to receipt (or non-receipt) of regulatory approvals required in connection with the transaction and the timing of receipt of such approvals; the possibility that other approvals or conditions of the transaction may not be received or satisfied on a timely basis or at all; changes in the expected timing for the closing of the transaction; business disruption during or after the transaction; diversion of management time on transaction-related issues; the ability to retain members of Bausch + Lomb’s management team; the risks associated with the reaction of customers and other parties to such a transaction; the impact of such transaction on relationships with customers, suppliers, employees and other business counterparties; the risk that the proposed distribution of Bausch + Lomb common stock to Bausch Health stockholders may not occur as or when expected or at all; and other events that could adversely impact the completion of the transaction, including industry or economic conditions beyond Bausch Health’s control. In particular, Bausch Health cannot guarantee that any IPO or distribution will occur, or that such transaction or transactions will occur on the time, in the manner or on the terms provided by Bausch Health. In addition, actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health’s overall business, including those described in more detail in Bausch Health’s most recent Annual Report on Form 10-K and detailed from time to time in other documents filed by Bausch Health. with the United States Securities and Exchange Commission and Canadian securities regulators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or related to the COVID-19 pandemic, including a possible resurgence of the virus and its variants and its impact on access to products and services. health care, the availability and use of effective vaccines, the imposition of new social restrictions, disruptions to Bausch Health’s supply chain and distribution channels, or the ongoing macroeconomic and health care recovery following the impacts of the COVID-19 pandemic.

Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual results, except as required by law.